Press Releases

14.12.2010

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the...

24.11.2010

MOLOGEN AG announces that the clinical study with the colorectal cancer medicine MGN1703, which is already underway in Germany and Austria, has been granted permission by the competent French authorities and the national ethics commission to also be...

11.11.2010

MOLOGEN AG very successfully continued its activities in the third quarter 2010. As the company reported when it published its quarterly numbers, in the past nine month the focus of its R&D activities was on the preparation and execution of the...

01.11.2010

As the company disclosed today, the claim against MOLOGEN AG was rejected and the claimant sentenced to reimburse costs. Background was the dispute about returning a product license for the region of India for the cell-based gene therapy against...

30.09.2010

MOLOGEN AG has taken a significant step forward in the development of its cancer medication. A further evaluation sequence of data from the company’s clinical study shows by means of biomarkers the potential of the active ingredient in the therapy...

12.08.2010

  • Important interim goals have been reached for the colorectal and kidney cancer drugs
  • Increase in R&D expenditures due to the start of the phase II study with colorectal cancer drug
  • Funding received for the development of...

22.06.2010

The Berlin-based biotechnology company MOLOGEN AG has received approval from the responsible German health authority, the Paul-Ehrlich-Institut, to carry out a phase I/II clinical study with its innovative new MGN1601 cancer medicine. MGN1601 is a...

   

Displaying results 1 bis 7 von 15

Page 1

Page 2

Page 3

next

   

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com